Stealth® liposomes: from theory to product

doi:10.1016/S0169-409X(96)00456-5

Advanced Drug Delivery Reviews

Volume 24, Issues 2–3, 17 March 1997, Pages 165-177

https://doi.org/10.1016/S0169-409X(96)00456-5 Get rights and content

Abstract

The development of an effective anti-cancer liposomal formulation — doxorubicin in sterically stabilized liposomes — will be discussed. We shall argue that for many tumors the necessary condition for an effective anti-cancer activity of systemically administered liposomal doxorubicin formulation is the long circulation life of liposomes in blood and stable drug encapsulation. Theoretical basis for stabilization of liposomes in biological environments and for the stabilization of drug encapsulation will be shown. When a formulation with acceptable stability was obtained it was tested in pre-clinical models and simultaneously scaled-up and it entered into clinical studies. After successfully passing all these tests, doxorubicin in sterically stabilized liposomes (Doxil^™ by Sequus Pharmaceuticals, Inc., Menlo Park, CA) was approved by Food and Drug Administration and is commercially available since late 1995.

References (70)

LasicD.D. et al.
Sterically stabilized liposomes: a hypothesis on the molecular origin of extended circulation times
Biochim. Biophys. Acta
(1991)
LasicD.D. et al.
Gelation of liposome interior
FEBS Lett.
(1992)
HaranG. et al.
Biochim. Biophys. Acta
(1993)
FrezardF. et al.
Biochim. Biophys. Acta
(1994)
deGennesP.G.
Polymers at interface
Adv. Colloid Interface Sci.
(1987)
KuhlT. et al.
Modulation of interaction forces beteen bilayers exposing short chained ethylene oxide head groups
Biophys. J.
(1994)
TorchilinV.P. et al.
Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo
Biochim. Biophys. Acta
(1994)
UsterP.S. et al.
Insertion of poly(ethyleneglycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation times
FEBS Lett.
(1996)
BlumeG. et al.
Specific targeting with PEG-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times
Biochim. Biophys. Acta
(1993)
HansenC. et al.
Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling process
Biochim. Biophys. Acta
(1995)

KenworthyA.K. et al.

Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached PEG

Biophys. J.

(1995)

BurnerH. et al.

Surface potential of lipid monolayers with grafted polyethylene glycol chains

J. Colloid. Interface Sci.

(1994)

WinterhalterM. et al.

Interaction of PEG with lipid monolayers

Biophys. J.

(1995)

JanzenJ. et al.

Interfacial thickness of liposomes containing PEG-cholesterol from electrophoresis

Biophys. J.

(1996)

JeonS.I. et al.

J. Colloid Interface Sci.

(1991)

LasicD.D.

The Applications of Liposomes

MaruyamaK. et al.

Targetability of novel immunoliposomes modefied with amhipathic PEGs conjugated at their distal terminals to monoclonal antibodies

Biochim. Biophys. Acta

(1995)

KirpotinD. et al.

Liposomes with detachable polymer coating: destabilization and fusion of DOPE vesicles triggered by cleavage of surface grafted PEG

FEBS Lett.

(1996)

LasicD.D. et al.

Liposomes and polymers in drug and gene delivery

Curr. Op. Solid State Mat. Sci.

(1996)

NeedhamD. et al.

Repulsive interactions and mechanical stability of polymer grafted lipid bilayers

Biochim. Biophys. Acta

(1992)

LasicD.D. et al.

Liposomes Revisited

Science

(1995)

LasicD.D.

Liposomes: from Physics to Applications

LasicD.D.

Doxorubicin in sterically stabilized liposomes

Nature

(1996)

PapahadjopoulosD. et al.

Permeability properties of phospholipid membranes: effect of cholesterol and temperature

Biochim. Biophys. Acta

(1972)

GregoriadisG. et al.

The phosphoilipid component of SUV controls the rate of clearance of entrapped solution from the circulation

FEBS Lett.

(1980)

LasicD.D. et al.

Stealth liposomes — a prototypical biomaterial

Chem. Rev.

(1995)

NapperD.H.

Polymer Stabilization of Colloidal Dispesions

(1983)

NicholsJ.W. et al.

Cathecolamine uptake and concentration by liposomes maintaining pH gradients

Biochim. Biophys. Acta

(1976)

BolotinE.M. et al.

Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes

J. Lip. Res.

(1994)

CˇehB. et al.

A rigorous theory of vesicle loading

Langmuir

(1995)

LasicD.D. et al.

Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery

Biochim. Biophys. Acta

(1995)

FrezardF.J.

J. Liposome Res.

(1994)

LasicD.D.

Sterically stabilized vesicles

Angew. Chem. Int. Ed. Eng.

(1994)

BorisovO. et al.

Stabilization of colloidal dispersions by grafted polymers

Cited by (202)

Discrete polyethylene glycol derivatives as a potent impetus for next-generation biomedicines
2023, Giant
PEGylation, which covalently modifies small-molecule drugs, peptides and proteins with polyethylene glycol (PEG) to improve their pharmacokinetics and efficacy, has become one of the most widely used drug modification techniques. However, PEG and its derivatives have been verified to be immunogenic and antigenic, which directly lead to side effects such as accelerated blood clearance (ABC) phenomenon and allergic reactions to PEGylated drugs or PEG excipients. Recent development of single molecular weight discrete PEG synthesis methodology have led to continuous and extensive focus on the difference in biological activity between conventional polydisperse PEG and single molecular weight precise PEG. Discrete PEG has demonstrated obvious advantages in resisting protein adsorption, cell adhesion and enhancing drug efficacy. These preliminary results not only confirm the significant impact of PEG chain polydispersity on its biological effect, but also reveal the possibility and potential advantages of using discrete PEG to reduce the immunogenicity and antigenicity. Hopefully, single chemical structure and molecular weight ensure the batch repeatability of newly developed discrete PEG products, and facilitate the understanding of their physicochemical properties and biological effects that promoting the clinical conversion of precise PEG drugs.
Glucagon-modified Liposomes Delivering Thyroid Hormone for Anti-obesity Therapy
2023, Archives of Medical Research
Thyroid hormones (active form T3) are naturally potent compounds that influence energy expenditure, cholesterol metabolism, and fat oxidation. T3 would be an effective anti-obesity drug if it would not be delivered to the heart and bones, which leads to serious side effects, such as cardiovascular and bone thyrotoxicity, muscle wasting, and so on.
In this study, we designed a targeted drug delivery system that is a glucagon-modified liposome to deliver T3 to the liver and adipose tissues.
The liposomes exhibited excellent properties, including uniform nanoscale particle size, good physicochemical stability, and adequate drug release behavior. More importantly, the glucagon-modified liposomes were enriched in the liver, which minimized the undesired bone and cardiovascular thyrotoxicity of T3. Compared to the control group, T3-loading glucagon-modified liposomes could effectively decrease body weight, reverse hepatic steatosis, and correct hyperlipidemia and hyperglycemia in ob/ob mice, without the undesired cardiovascular and bone thyrotoxicity.
These findings indicate that delivery of thyroid hormone by glucagon-modified liposomes may provide an effective strategy for anti-obesity therapy.
Recent advances in using liposomes for delivery of nucleic acid-based therapeutics
2023, OpenNano
Nucleic acid therapeutics are rapidly expanding because of recent advancements in production and purification. This class of therapeutics may change the field of disease treatment and personalized medicine since it can cure diseases. However, drug delivery systems are crucial for these therapeutics to fulfill their potential. Liposomes have long been considered ideal platforms for systemic drugs delivery. Considering the development in cancer therapeutics, this work emphases on the current advancements in liposomes’ Nano-formulations, functionalization, and design and how it has been applied to nucleic acid therapeutics. Accordingly, this review covers the literature that deals with liposomes in nucleic acid therapy.
Engineered liposomes as drug delivery and imaging agents
2023, Design and Applications of Theranostic Nanomedicines
Liposomes have been researched upon for a variety of ailments, including cancer. They boost therapeutic efficacy by increasing drug absorption while preventing or lowering fast degradation and associated side effects, extending the biological half-life, and lowering toxicity. Liposomes are efficient in the fact that they are composed of biocompatible and biodegradable lipids which makes them inert and non-immunogenic. Functionalization with ligands makes them more target specific in delivering the entrapped drugs at the intended site. Both hydrophilic and hydrophobic compounds are efficiently entrapped in liposomes, and they have been exploited as a diagnostic tool in recent breakthroughs in multimodality imaging to better diagnose diseases and monitor therapies.
The present chapter highlights the formulation advancement and applications of several engineered liposomes for delivery of drug and imaging agent either as individual or in combinatorial therapy.
Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: An update
2022, International Journal of Pharmaceutics
Liposomes have several advantages, such as the ability to be employed as a carrier/vehicle for a variety of drug molecules and at the same time they are safe and biodegradable. In the recent times, compared to other delivery systems, liposomes have been one of the most well-established and commercializing drug products of new drug delivery methods for majority of therapeutic applications. On the other hand, it has several limitations, particularly in terms of stability, which impedes product development and performance. In this review, we reviewed all the potential instabilities (physical, chemical, and biological) that a formulation development scientist confronts throughout the development of liposomal formulations as along with the ways to overcome these challenges. We have also discussed the effect of microbiological contamination on liposomal formulations with a focus on the use of sterilization methods used to improve the stability. Finally, we have reviewed quality control techniques and regulatory considerations recommended by the agencies (USFDA and MHLW) for liposome drug product development.
Synthesis and Evaluation of High Functionality and Quality Cell-penetrating Peptide Conjugated Lipid for Octaarginine Modified PEGylated Liposomes In U251 and U87 Glioma Cells
2022, Journal of Pharmaceutical Sciences
The use of peptide ligand modified PEGylated liposomes has been widely investigated for tumor targeting. Peptides are mainly inserted in the liposomal lipid bilayer using PEG_2K-lipid spacer (Peptide-PEG_2K-DSPE). However, a lower cellular uptake from longer nonlinear PEG_2K spacer was reported, we here synthesized a high functionality and quality (HFQ) lipid with a short, linear serine-glycine repeated peptide [(SG)₅] spacer. The objective of the current study is to develop novel octaarginine (R₈) peptide-HFQ lipid grafted PEGylated liposomes for glioma cells targeting. In vitro liposomes characterization showed that the mean particle size of all liposomal formulations was in the nano-scale range < 120 nm, with a small PDI value (i.e. ∼0.2) and had a spherical shape under Transmission Electron Microscope, indicating a homogenous particle size distribution. The flow cytometry in vitro cellular association data with U251 MG and U87 cells revealed that 1.5% R₈-(SG)₅-lipid-PEGylated liposomes exhibited significantly higher cellular association of ∼15.87 and 7.59-fold than the conventional R₈-PEG_2K-lipid-PEGylated liposomes (10.4 and 6.19-fold), respectively, relative to the unmodified PEGylated liposomes. Moreover, intracellular distribution studies using confocal laser scanning microscopy (CLSM) corroborated the results of the in vitro cell association. The use of ligand-HFQ-lipid liposomes could be a potential alternative to ligand-PEG_2K-lipid-modified liposomes as a drug delivery system for tumor targeting.

View all citing articles on Scopus

: Due to their invisibility to the body's defence system sterically stabilized liposomes are often called also Stealth® liposomes (a registered trademark name of Sequus Pharmaceuticals, Inc., Menlo Park, California.

View full text

Stealth® liposomes: from theory to product

Abstract

Biochim. Biophys. Acta

FEBS Lett.

Biochim. Biophys. Acta

Biochim. Biophys. Acta

Adv. Colloid Interface Sci.

Biophys. J.

Biochim. Biophys. Acta

FEBS Lett.

Biochim. Biophys. Acta

Biochim. Biophys. Acta

Biophys. J.

J. Colloid. Interface Sci.

Biophys. J.

Biophys. J.

J. Colloid Interface Sci.

Biochim. Biophys. Acta

FEBS Lett.

Curr. Op. Solid State Mat. Sci.

Biochim. Biophys. Acta

Liposomes Revisited

Science

Liposomes: from Physics to Applications

Doxorubicin in sterically stabilized liposomes

Nature

Permeability properties of phospholipid membranes: effect of cholesterol and temperature

Biochim. Biophys. Acta

The phosphoilipid component of SUV controls the rate of clearance of entrapped solution from the circulation

FEBS Lett.

Stealth liposomes — a prototypical biomaterial

Chem. Rev.

Polymer Stabilization of Colloidal Dispesions

Cathecolamine uptake and concentration by liposomes maintaining pH gradients

Biochim. Biophys. Acta

Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes

J. Lip. Res.

A rigorous theory of vesicle loading

Langmuir

Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery

Biochim. Biophys. Acta

J. Liposome Res.

Sterically stabilized vesicles

Angew. Chem. Int. Ed. Eng.

Stabilization of colloidal dispersions by grafted polymers